Učitavanje...
The evolving treatment paradigm in myelofibrosis
Myelofibrosis (MF) is a BCR–ABL1-negative myeloproliferative neoplasm diagnosed de novo or developed from essential thrombocythemia (ET) or polycythemia vera (PV). Average survival of a patient with MF is 5–7 years. Disease complications include fatigue, early satiety, pruritus, painful splenic infa...
Spremljeno u:
| Glavni autor: | |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Informa Healthcare
2013
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3545544/ https://ncbi.nlm.nih.gov/pubmed/22793267 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2012.710905 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|